Discover how Merck used the Cyto-Mine® to screen primary B cells (human and rodent cells) for antibodies specific to certain antigens.

The advancement of therapeutic antibody discovery faces time and cost challenges. Merck R&D scientists address this by employing Sphere Fluidics’ microfluidics picodroplet technology.

Rapid high-throughput screening of primary antibody-secreting cells from rodent and human donors, demonstrating specific antibody binding to recombinant antigens, showcases the streamlined and automated workflow of Sphere Fluidics’ Cyto-Mine® platform in antibody discovery projects.

Key takeaways within this application note:

• Human plasma blasts post-tetanus toxoid vaccination were isolated and screened to identify tetanus-specific antibodies.
• The Cyto-Mine® was used on rodent B cells immunized with Cancer Related Antigen (CRA) to explore immune response diversity.
• This app note demonstrates the ability to process millions of cells efficiently in a single day, accelerating the antibody discovery process.

Download to continue reading…